Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 1158121

Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato- oncology survey in 34 countries


Kandolf Sekulovic, L.; Guo, J.; Agarwala, S.; Hauschild, A.; McArthur, G.; Cinat, G.; Wainstein, A.; Caglevic, C.; Lorigan, P.; Gogas, H. et al.
Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato- oncology survey in 34 countries // European Journal of Cancer, 104 (2018), 201-209 doi:10.1016/j.ejca.2018.09.013 (međunarodna recenzija, članak, ostalo)


CROSBI ID: 1158121 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato- oncology survey in 34 countries

Autori
Kandolf Sekulovic, L. ; Guo, J. ; Agarwala, S. ; Hauschild, A. ; McArthur, G. ; Cinat, G. ; Wainstein, A. ; Caglevic, C. ; Lorigan, P. ; Gogas, H. ; Alvarez, M. ; Duncombe, R. ; Lebbe, C. ; Peris, K. ; Rutkowski, P. ; Stratigos, A. ; Forsea, A.-M. ; De La Cruz Merino, L. ; Kukushkina, M. ; Dummer, R. ; Hoeller, C. ; Gorry, C. ; Bastholt, L. ; Herceg, D. ; Neyns, B. ; Vieira, R. ; Arenberger, P. ; Bylaite- Bucinskiene, M. ; Babovic, N. ; Banjin, M. ; Putnik, K. ; Todorovic, V. ; Kirov, K. ; Ocvirk, J. ; Zhukavets, A. ; Ymeri, A. ; Stojkovski, I. ; Garbe, C.

Izvornik
European Journal of Cancer (0959-8049) 104 (2018); 201-209

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, ostalo

Ključne riječi
Access ; Immunooncology ; Innovative medicines ; Metastatic melanoma ; Targeted therapy ; Treatment.

Sažetak
According to data from recent studies from Europe, a large percentage of patients have restricted access to innovative medicines for metastatic melanoma. Melanoma World Society and European Association of Dermato-oncology conducted a Web-based survey on access to first-line recommended treatments for metastatic melanoma by current guidelines (National Comprehensive Center Network, European Society for Medical Oncology [ESMO] and European Organization for Research and Treatment of Cancer/European Association of Dermato-oncology/European dermatology Forum) among melanoma experts from 27 European countries, USA, China, Australia, Argentina, Brazil, Chile and Mexico from September 1st, 2017 to July 1st, 2018. Data on licencing and reimbursement of medicines and the number of patient treated were correlated with the data on health expenditure per capita (HEPC), Mackenbach score of health policy performance, health technology assessment (HTA), ASCO and ESMO Magnitude of clinical benefit scale (ESMO MCBS) scores of clinical benefit and market price of medicines. Regression analysis for evaluation of correlation between the parameters was carried out using SPSS software. The estimated number of patients without access in surveyed countries was 13768. The recommended BRAFi + MEKi combination and anti-PD1 immunotherapy were fully reimbursed/covered in 19 of 34 (55.8%) and 17 of 34 (50%) countries, and combination anti-CTLA4+anti-PD1 in was fully covered in 6 of 34 (17.6%) countries. Median delay in reimbursement was 991 days, and it was in significant correlation with ESMO MCBS (p = 0.02), median market price (p = 0.001), HEPC and Mackenbach scores (p < 0.01). Price negotiations or managed entry agreements (MEAs) with national authorities were necessary for reimbursement. In conclusion, great discrepancy exists in metastatic melanoma treatment globally. Access to innovative medicines is in correlation with economic parameters as well as with healthcare system performance parameters. Patient-oriented drug development, market access and reimbursement pathways must be urgently found.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti



POVEZANOST RADA


Profili:

Avatar Url Davorin Herceg (autor)

Poveznice na cjeloviti tekst rada:

doi

Citiraj ovu publikaciju:

Kandolf Sekulovic, L.; Guo, J.; Agarwala, S.; Hauschild, A.; McArthur, G.; Cinat, G.; Wainstein, A.; Caglevic, C.; Lorigan, P.; Gogas, H. et al.
Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato- oncology survey in 34 countries // European Journal of Cancer, 104 (2018), 201-209 doi:10.1016/j.ejca.2018.09.013 (međunarodna recenzija, članak, ostalo)
Kandolf Sekulovic, L., Guo, J., Agarwala, S., Hauschild, A., McArthur, G., Cinat, G., Wainstein, A., Caglevic, C., Lorigan, P. & Gogas, H. (2018) Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato- oncology survey in 34 countries. European Journal of Cancer, 104, 201-209 doi:10.1016/j.ejca.2018.09.013.
@article{article, author = {Kandolf Sekulovic, L. and Guo, J. and Agarwala, S. and Hauschild, A. and McArthur, G. and Cinat, G. and Wainstein, A. and Caglevic, C. and Lorigan, P. and Gogas, H. and Alvarez, M. and Duncombe, R. and Lebbe, C. and Peris, K. and Rutkowski, P. and Stratigos, A. and Forsea, A.-M. and De La Cruz Merino, L. and Kukushkina, M. and Dummer, R. and Hoeller, C. and Gorry, C. and Bastholt, L. and Herceg, D. and Neyns, B. and Vieira, R. and Arenberger, P. and Bylaite- Bucinskiene, M. and Babovic, N. and Banjin, M. and Putnik, K. and Todorovic, V. and Kirov, K. and Ocvirk, J. and Zhukavets, A. and Ymeri, A. and Stojkovski, I. and Garbe, C.}, year = {2018}, pages = {201-209}, DOI = {10.1016/j.ejca.2018.09.013}, keywords = {Access, Immunooncology, Innovative medicines, Metastatic melanoma, Targeted therapy, Treatment.}, journal = {European Journal of Cancer}, doi = {10.1016/j.ejca.2018.09.013}, volume = {104}, issn = {0959-8049}, title = {Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato- oncology survey in 34 countries}, keyword = {Access, Immunooncology, Innovative medicines, Metastatic melanoma, Targeted therapy, Treatment.} }
@article{article, author = {Kandolf Sekulovic, L. and Guo, J. and Agarwala, S. and Hauschild, A. and McArthur, G. and Cinat, G. and Wainstein, A. and Caglevic, C. and Lorigan, P. and Gogas, H. and Alvarez, M. and Duncombe, R. and Lebbe, C. and Peris, K. and Rutkowski, P. and Stratigos, A. and Forsea, A.-M. and De La Cruz Merino, L. and Kukushkina, M. and Dummer, R. and Hoeller, C. and Gorry, C. and Bastholt, L. and Herceg, D. and Neyns, B. and Vieira, R. and Arenberger, P. and Bylaite- Bucinskiene, M. and Babovic, N. and Banjin, M. and Putnik, K. and Todorovic, V. and Kirov, K. and Ocvirk, J. and Zhukavets, A. and Ymeri, A. and Stojkovski, I. and Garbe, C.}, year = {2018}, pages = {201-209}, DOI = {10.1016/j.ejca.2018.09.013}, keywords = {Access, Immunooncology, Innovative medicines, Metastatic melanoma, Targeted therapy, Treatment.}, journal = {European Journal of Cancer}, doi = {10.1016/j.ejca.2018.09.013}, volume = {104}, issn = {0959-8049}, title = {Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato- oncology survey in 34 countries}, keyword = {Access, Immunooncology, Innovative medicines, Metastatic melanoma, Targeted therapy, Treatment.} }

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE


Citati:





    Contrast
    Increase Font
    Decrease Font
    Dyslexic Font